Business Context and Reporting Period
This Form 8-K filing by Supernus Pharmaceuticals, Inc. covers events occurring on December 5 and December 6, 2018. The report focuses on clinical trial results for SPN-812, a drug candidate for the treatment of attention deficit hyperactivity disorder (ADHD) in children.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical milestones rather than a periodic financial statement.
Material Changes and Clinical Results
- Positive Phase III Results: On December 6, 2018, the Company announced positive topline results from two pivotal Phase III studies (P301 and P303) of SPN-812 in children.
- Primary Endpoint Met: The trials demonstrated statistically significant improvement in ADHD symptoms from baseline to the end of the study as measured by the ADHD Rating Scale-5.
- Dosing and Safety: Doses of 100mg and 200mg (Study P301) and 200mg and 400mg (Study P303) were effective and well tolerated.
Outlook, Guidance, and Management Commentary
- Upcoming Data: Topline data from the first adolescent Phase III trial (P302) is expected by the end of December 2018. Data from the second adolescent trial (P304) is expected by the end of the first quarter of 2019.
- Regulatory Timeline: The Company expects to submit a New Drug Application (NDA) for SPN-812 in the second half of 2019.
- Commercial Launch: Pending FDA approval, the Company plans to launch SPN-812 in the second half of 2020.
Investor Verification Checklist
- Verify the full statistical data and safety profile details in the attached press releases (Exhibits 99.1 and 99.2).
- Monitor the announcement of topline data for adolescent trials P302 and P304 as scheduled.
- Confirm the submission of the New Drug Application in the second half of 2019.
- Review FDA review timelines and potential approval dates for the 2020 launch target.